Table 4.

Primary composite CVD endpoints in SPRINT and ACCORD-BP

Study	N at risk*	N events	Proportion of total events*	IR per 1000 person-years (95% bootstrapped CI)
SPRINT
SBP≥130 or DBP≥80 and SBP<140 and DBP<90, not on BP medications at baseline	247	10	2%	12.9 (5.3,22.0)
SBP ≥ 140 or DBP ≥ 90, not on BP medications at baseline	561	21	4%	12.2 (7.5, 17.9)
SBP≥130 or DBP≥80 and SBP<140 and DBP<90, on BP medications at baseline	2599	133	24%	16.2 (13.5, 19.0)
SBP ≥ 140 or DBP ≥ 90, on BP medications at baseline	4092	285	51%	22.4 (19.9, 25.0)
ACCORD-BP
SBP≥130 or DBP≥80 and SBP<140 and DBP<90, not on BP meds at baseline	227	14	3%	12.8 (6.8, 20.2)
SBP≥140 or DBP≥90, not on BP meds at baseline	373	25	6%	13.9 (8.8, 19.5)
SBP≥130 or DBP≥80 and SBP<140 and DBP<90, on BP meds at baseline	1584	147	33%	20.0 (16.9, 23.5)
SBP≥140 or DBP≥90, on BP meds at baseline	2549	259	58%	21.8 (19.3, 24.5)

Composite primary outcome for ACCORD is nonfatal MI, nonfatal stroke, or CVD death; composite primary outcome for SPRINT is MI, HF, stroke, angina, or CVD death.

Abbreviations: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; IR, incident rate.

^*An additional 113 events occurred in 1,749 participants with a SBP <130 and a DBP <80 mm Hg at randomization. Only 74 participants in this category were not on medications at baseline.